Regulatory approval

Published by the Food and Drug Administration. Approved

ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.

This is written in the approval document.

Citation

GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib